These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

731 related articles for article (PubMed ID: 31362750)

  • 1. Combined score of pretreatment platelet count and CA125 level (PLT-CA125) stratified prognosis in patients with FIGO stage IV epithelial ovarian cancer.
    Chen JP; Huang QD; Wan T; Tu H; Gu HF; Cao JY; Liu JH
    J Ovarian Res; 2019 Jul; 12(1):72. PubMed ID: 31362750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of pretreatment thrombocytosis in epithelial ovarian cancer.
    Okunade KS; Dawodu O; Adenekan M; Nwogu CM; Awofeso O; Ugwu AO; Salako O; John-Olabode S; Olowoselu OF; Anorlu RI
    Niger J Clin Pract; 2020 Aug; 23(8):1141-1147. PubMed ID: 32788493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
    Yang HM; Lou G
    Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum CA125 levels predict outcome of interval debulking surgery after neoadjuvant chemotherapy in patients with advanced ovarian cancer.
    Zhang D; Jiang YX; Luo SJ; Zhou R; Jiang QX; Linghu H
    Clin Chim Acta; 2018 Sep; 484():32-35. PubMed ID: 29702068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma.
    Li Z; Yin H; Ren M; Shen Y
    Med Sci Monit; 2020 Sep; 26():e925051. PubMed ID: 32908118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative change in CA125 is an independent prognostic factor for improved clinical outcome in advanced ovarian cancer.
    Timmermans M; Zwakman N; Sonke GS; Van de Vijver KK; Duk MJ; van der Aa MA; Kruitwagen RF
    Eur J Obstet Gynecol Reprod Biol; 2019 Sep; 240():364-369. PubMed ID: 31400565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the value of preoperative CYFRA21-1 in the diagnosis and prognosis of epithelial ovarian cancer in conjunction with CA125.
    Jin C; Yang M; Han X; Chu H; Zhang Y; Lu M; Wang Z; Xu X; Liu W; Wang F; Ju S
    J Ovarian Res; 2019 Nov; 12(1):114. PubMed ID: 31767040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.
    Lee M; Chang MY; Yoo H; Lee KE; Chay DB; Cho H; Kim S; Kim YT; Kim JH
    Yonsei Med J; 2016 May; 57(3):580-7. PubMed ID: 26996555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High grade, advanced, serous ovarian cancer with low serum CA125 levels.
    Asali A; Haj-Yehia N; Zehavi T; Perry T; Beiner M; Fishman A; Kadan Y
    J Obstet Gynaecol; 2021 Oct; 41(7):1107-1111. PubMed ID: 33427544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of the change pattern of serum CA125 level for judging prognosis and diagnosing recurrences of epithelial ovarian cancer.
    Yang ZJ; Zhao BB; Li L
    J Ovarian Res; 2016 Sep; 9(1):57. PubMed ID: 27629537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-treatment prognostic nutritional index is superior to platelet count in predicting disease-specific survival in patients with epithelial ovarian cancer.
    Komura N; Mabuchi S; Yokoi E; Shimura K; Kawano M; Matsumoto Y; Kimura T
    Int J Gynecol Cancer; 2019 Jul; 29(6):1057-1063. PubMed ID: 31203199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapy.
    Juretzka MM; Barakat RR; Chi DS; Iasonos A; Dupont J; Abu-Rustum NR; Poynor EA; Aghajanian C; Spriggs D; Hensley ML; Sabbatini P
    Gynecol Oncol; 2007 Jan; 104(1):176-80. PubMed ID: 16996584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and prognostic factors of patients with epithelial ovarian cancer subjected to first-line treatment: a retrospective study of 251 cases.
    Fu Y; Wang X; Pan Z; Xie X
    Front Med; 2014 Mar; 8(1):91-5. PubMed ID: 24370920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.
    Zwakman N; van de Laar R; Van Gorp T; Zusterzeel PL; Snijders MP; Ferreira I; Massuger LF; Kruitwagen RF
    J Gynecol Oncol; 2017 Jan; 28(1):e7. PubMed ID: 27670261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative plasma D-dimer level is a useful prognostic marker in ovarian cancer.
    Yamada Y; Kawaguchi R; Iwai K; Niiro E; Morioka S; Tanase Y; Kobayashi H
    J Obstet Gynaecol; 2020 Jan; 40(1):102-106. PubMed ID: 31335252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer.
    Zhao D; Wang X; Zhang W
    BMC Cancer; 2018 Mar; 18(1):328. PubMed ID: 29580231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    Feng Z; Wen H; Bi R; Duan Y; Yang W; Wu X
    BMC Cancer; 2016 Jan; 16():43. PubMed ID: 26817451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CA125 nadir concentration is an independent predictor of tumor recurrence in patients with ovarian cancer: a population-based study.
    van Altena AM; Kolwijck E; Spanjer MJ; Hendriks JC; Massuger LF; de Hullu JA
    Gynecol Oncol; 2010 Nov; 119(2):265-9. PubMed ID: 20797777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer.
    Zhou M; Li L; Wang X; Wang C; Wang D
    Cell Physiol Biochem; 2018; 46(1):178-186. PubMed ID: 29587273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.